Analyst rates Kimbell Royalty Partners a Buy at $15.15, citing an 11% normalized yield and a $17.29 target over 12–18 months.
A study in Applied Network Science shows that converting network traffic features into natural language significantly ...
Host Kevin Kelly, Kelly Intelligence Founder, CEO, and CCO, and his panel of experts weigh in on today's market relief, ...
Phillips 66 delivered a remarkable Q3 2026, with $6.28B in refining EBITDA, nearly matching my estimate. See why I rate PSX ...
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting® 2026 and simultaneously published in AASLD’s ...
<?xml encoding="utf-8" ?> OptimizeRx OPRX reported third-quarter financial results on Wednesday. The transcript from the ...
This article is the implementation guide for stagnation and loop detection. The events at the beginning are hypothetical ...
<?xml encoding="utf-8" ?> ODDITY Tech ODD reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. This content is ...
In recent decades, however, governments’ commitment to the cause of peace has weakened. Millions of people took to the streets in hundreds of cities to oppose the U.S.-led invasion of Iraq in 2003, ...
Operator: Good day, and welcome to the InfuSystem Holdings Third Quarter 2026 Financial Results Conference Call. [Operator ...
Mirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late ...
Mirum reports a 59 per cent combined response with weekly brelovitug in AZURE-4 and plans an FDA biologics filing in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results